Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 20,690 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral Blood Clear all

Conditions: Atrial Fibrillation
Interventions: Carotid Ultrasound; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 95 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Head and Neck Squamous Cell Cancer
Interventions: Cisplatin, cetuximab, Radiation; Drug · Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cancer
Interventions: GSK2118436, Midazolam; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Nashville, Tennessee + 1 more

Conditions: Healthy
Interventions: Aspirin 81 mg, Celecoxib 200mg capsule; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Coronary Syndrome
Interventions: intensive LDL-lowering therapy, standard statin monotherapy; Device · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 31 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Dallas, Texas

Conditions: Acquired Immunodeficiency Syndrome, HIV Infection
Interventions: White blood cell infusion; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Atrophy of Edentulous Alveolar Ridge, Partial Edentulism
Interventions: Two implant designs in a Sinus Bone Augmentation Procedure, Two implant designs in a Sinus Floor Elevation Procedure; Device
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: 21 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Choroidal Melanoma
Interventions: Ranibizumab 2 mg, 0.5 mg Ranibizumab; Drug
Lead sponsor: New England Retina Associates; Other
Eligibility: 50 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Hamden, Connecticut

Conditions: Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome
Interventions: Stem cell transplant, Fludarabine monophosphate, Total lymphoid irradiation, Busulfan, anti-thymocyte globulin; Procedure · Drug · Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 35 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Unresectable Melanoma
Interventions: Ipilimumab; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glucose Intolerance
Interventions: Liquid vinegar, vinegar pill; Dietary Supplement
Lead sponsor: Arizona State University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Alzheimer Disease
Interventions: Tau Positron emission tomography (PET), Fluorodeoxyglucose (FDG) Positron emission tomography (PET), Cerebrospinal fluid (CSF) Biomarkers, Blood Biomarkers, Rating Scales, PU-AD, Placebo; Radiation · Diagnostic Test · Behavioral + 1 more
Lead sponsor: Samus Therapeutics, Inc.; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more

Conditions: Severe Hemophilia A
Interventions: VWF/FVIII concentrates; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Duarte, California

Conditions: Respiratory Infection Virus, COVID -19, RSV, FLU
Interventions: Component A0, Component A1, Component A2, Component B; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: Not listed
Enrollment: 25,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: La Jolla, California • San Ysidro, California

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, pH Low Insertion Peptide-exatecan Conjugate CBX-12; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Leukemia, Acute Lymphoblastic, Multiple Myeloma, Myelofibrosis
Interventions: Molecular diagnostic testing; Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Melanoma
Interventions: Nivolumab, Ipilimumab, Cabozantinib; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey

Conditions: Hypertension (HTN)
Interventions: Practice support And Community Engagement (PACE); Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: Blood Sample; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: Blood Draw; Other
Lead sponsor: Wolfram Samlowski; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Osteogenesis Imperfecta
Interventions: Fresolimumab; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Portland, Oregon • Houston, Texas

Conditions: Hypertension
Interventions: Remote patient monitoring for hypertension, Remote patient monitoring with care management; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 17,290 participants
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Choroidal Neovascularization
Interventions: Faricimab, Ranibizumab, Sham Procedure; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 52
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 46 more

Conditions: Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
Interventions: Nivolumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Search by objective public record fields.

Arterial Stiffness and Atrial Fibrillation

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

Timed Aspirin Chronobiome Study

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

White Blood Cell Infusions to Treat HIV Infection

Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants After Sinus Floor Elevation

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Stem Cell Transplant for Bone Marrow Failure Syndromes

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Daily Vinegar Ingestion and 24-Hour Blood Glucose Control

To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)

Preparedness Through Respiratory Virus Epidemiology and Community Engagement

Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers

iCare for Cancer Patients

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

Actions to Decrease Disparities in Risk and Engage in Shared Support for Blood Pressure Control (ADDRESS-BP) in Blacks

Prospective Validation Trial of Circulating Tumor Cells (CTCs) in Women With Metastatic Breast Cancer

Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

Hypertension Management Using Remote Patient Monitoring: Study 2

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers